J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on September 1, 2003

Papers In Press, published online ahead of print June 16, 2003
J. Lipid Res., doi:10.1194/jlr.M300059-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M300059-JLR200v1
44/9/1698    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siggins, S.
Right arrow Articles by Ehnholm, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siggins, S.
Right arrow Articles by Ehnholm, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on February 4, 2003
Revised on May 16, 2003
Accepted on June 5, 2003

Phospholipid transfer protein (PLTP) secreted by HepG2 cells resembles the high-activity PLTP form in human plasma

Sarah Siggins, Matti Jauhiainen, Vesa M. Olkkonen, Jukka Tenhunen, and Christian Ehnholm

Department of Molecular Medicine, National Public Health Institute, Helsinki FIN-00251

Corresponding Author: sarah.siggins{at}ktl.fi

Plasma phospholipid transfer protein (PLTP) is an important regulator of plasma high density lipoprotein (HDL) levels and HDL particle distribution. The protein is present in the circulation in two forms, one with high and the other with low phospholipid transfer activity. We have used the human hepatoma cell line, HepG2, as a model to study the PLTP secreted from hepatic cells. PLTP activity was secreted by the cells into serum-free culture medium as a function of time. However, modification of a previously established ELISA mass assay to include a denaturing sample pre-treatment with the anionic detergent sodium dodecyl sulphate (SDS) was required for the detection of the secreted PLTP protein. The HepG2 PLTP could be enriched by Heparin-Sepharose affinity chromatography and eluted in size-exclusion chromatography at a position corresponding to the size of 160 kDa. PLTP co-eluted with apoE but not with apoB-100 or apoA-I. A portion of PLTP was retained by an anti-apoE immunoaffinity column together with apoE, suggesting an interaction between these two proteins. Furthermore, antibodies against apoE but not those against apoB-100 or apoA-I were capable of inhibiting PLTP activity. These results show that the HepG2-derived PLTP resembles in several aspects the high-activity form of PLTP found in human plasma. The findings support a model in which PLTP is secreted by the liver as an active form that is, during lipid transfer processes between lipolysed chylomicrons/VLDL and HDL, converted into the low-activity complex.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
C. Christoffersen, M. Jauhiainen, M. Moser, B. Porse, C. Ehnholm, M. Boesl, B. Dahlback, and L. B. Nielsen
Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice
J. Biol. Chem., January 25, 2008; 283(4): 1839 - 1847.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. Liu, M. R. Hojjati, C. M. Devlin, I. H. Hansen, and X.-C. Jiang
Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion: Impact on Mouse Plasma Cholesterol Levels and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 190 - 196.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. Lee-Rueckert, R. Vikstedt, J. Metso, C. Ehnholm, P. T. Kovanen, and M. Jauhiainen
Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells
J. Lipid Res., August 1, 2006; 47(8): 1725 - 1732.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. C. Cheung and J. J. Albers
Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins
J. Lipid Res., June 1, 2006; 47(6): 1315 - 1321.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. M. Dallinga-Thie, A. van Tol, H. Hattori, P. C.N. Rensen, E. J.G. Sijbrands, and for the Diabetes Atorvastatin Lipid Intervention (
Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e?
Diabetes, May 1, 2006; 55(5): 1491 - 1496.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. T. Janis, S. Siggins, E. Tahvanainen, R. Vikstedt, K. Silander, J. Metso, A. Aromaa, M.-R. Taskinen, V. M. Olkkonen, M. Jauhiainen, et al.
Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample
J. Lipid Res., December 1, 2004; 45(12): 2303 - 2309.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.